Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
RESEARCH TOOLSreports
Neumora Therapeutics, Inc. (NMRA) Stock Price & Analysis
56 Followers
NMRA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.35 - $21.00
Previous Close$10.55
Volume404.26K
Average Volume (3M)523.89K
Market Cap
$1.68B
Enterprise Value$1.05B
Total Cash (Recent Filing)£509.56M
Total Debt (Recent Filing)£6.14M
Price to Earnings (P/E)-6.9
Beta0.88
Next Earnings
Mar 07, 2024EPS Estimate
-$0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding158,886,101
10 Day Avg. Volume666,627
30 Day Avg. Volume523,887
Standard Deviation0.25
R-Squared0.40
Alpha-0.13
Financial Highlights & Ratios
Price to Book (P/B)3.40
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$27.50Price Target Upside160.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Neumora Therapeutics, Inc. News
Ownership Overview
94.60% Insiders
0.62% Mutual Funds
2.81% Other Institutional Investors
1.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $9.35 and its highest was $21.00 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is Mar 07, 2024 which is 62 days ago.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on Nov 01, 2023. The company reported -$1.14 earnings per share for the quarter, missing the consensus estimate of -$0.347 by -$0.793.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -$0.55.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 158,886,110 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$1.14 in its last earnings report, missing expectations of -$0.347. Following the earnings report the stock price went up 3.261%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Among the largest hedge funds holding Neumora Therapeutics, Inc.’s share is GMT Capital Corp. It holds Neumora Therapeutics, Inc.’s shares valued at 2M.
---
Neumora Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.50 (160.66% Upside)
$27.50 (160.66% Upside)
Blogger Sentiment
Bearish
NMRA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 130.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-54.49%
Trailing 12-Months
Asset Growth
16.41%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.
---
NMRA Stock 12 Month Forecast
Average Price Target
$27.50
▲(160.66% Upside)
Technical Analysis
Best Analysts Covering NMRA
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-15.07%
reiterated a buy rating 23 days ago
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -15.07% per trade.
---